HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Interleukin-2 Receptors (IL 2 Receptor)

Subscribe to New Research on Interleukin-2 Receptors

Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.

Also Known As:

IL 2 Receptor; Interleukin 2 Receptor; Receptors, Interleukin 2; Receptors, Interleukin-2; IL-2 Receptor; IL2 Receptor; IL2 Receptors; Receptor, TCGF; T-Cell Growth Factor Receptor; TCGF Receptor; TCGF Receptors; IL 2 Receptors; Interleukin 2 Receptors; Receptor, IL-2; Receptor, IL2; Receptor, Interleukin 2; Receptors, IL 2; Receptors, IL2; Receptors, T Cell Growth Factor; Receptors, TCGF; T Cell Growth Factor Receptor; T Cell Growth Factor Receptors; IL-2 Receptors; Receptors, IL-2; Receptors, T-Cell Growth Factor; T-Cell Growth Factor Receptors

Networked: 1490 relevant articles (39 outcomes, 142 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Membrane Proteins: 5300
    - Cell Surface Receptors: 753
      - Immunologic Receptors: 8
        Cytokine Receptors: 788
        Interleukin Receptors: 68
        Interleukin-2 Receptors: 1490
        Interleukin-2 Receptor alpha Subunit: 201
        Interleukin-2 Receptor beta Subunit: 62
        Interleukin Receptor Common gamma Subunit: 26

Experts

1.	Gillies, Stephen D: 4 articles (12/2011 - 11/2004)
2.	Waldmann, Thomas A: 4 articles (01/2007 - 12/2003)
3.	Sachs, David H: 3 articles (08/2015 - 05/2013)
4.	Wang, Zhirui: 3 articles (08/2015 - 05/2013)
5.	Huang, Christene A: 3 articles (08/2015 - 05/2013)
6.	Zhang, Huiping: 3 articles (08/2015 - 05/2013)
7.	Waldmann, T A: 3 articles (03/2015 - 05/2000)
8.	Dang, Nam H: 3 articles (01/2015 - 10/2004)
9.	Roifman, Chaim M: 3 articles (10/2014 - 08/2006)
10.	Signore, Alberto: 3 articles (10/2012 - 10/2004)

Related Diseases

1.	Lymphoma (Lymphomas) 10/01/2011 - "The value of soluble IL-2 receptor antibody was 16,000U/ml. Intravascular lymphoma was suspected because of brain CT finding and IL-2 receptor antibody titer. " 02/01/2009 - "Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed. " 11/01/2005 - "Measurement of IL-2 receptor and biopsy with flow cytometry were necessary to work out the treatment strategy of the spinal malignant lymphoma. " 05/23/2000 - "Immunogold staining and electron microscopy show that IL-2 receptor alpha-subunits exhibit nonrandom surface distribution on human T lymphoma cells. " 07/15/1995 - "Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma."
2.	Leukemia 11/01/1996 - "IL-2-dependent clones established from the DN alphabeta T cell population in the PEC of IL-2 receptor alpha-chain transgenic B6 mice exhibited potent cytotoxicity against a series of B cell lineage leukemias and myelomas, such as CD5+BCL1 and MOPC, without affecting NK-susceptible targets. " 02/01/1994 - "This report describes that PHA, in vitro, induces the p55 IL-2 receptor subunit on initially p55-negative B-CLL cells and converts toxin-insensitive leukemia cells to a toxin-sensitive state." 11/01/1989 - "MT-1 and HUT-102 cell lines derived from patients with ATL were compared with Molt-4, a leukemia cell line that does not express IL-2 receptors in an uninduced state. " 01/01/1989 - "[Autoimmune reactions against interleukin-2 receptors in patients with blood system diseases and in experimental Rauscher retrovirus leukemia]." 01/01/1985 - "Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression."
3.	Hodgkin Disease (Hodgkin's Disease) 03/01/1998 - "The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. " 07/01/2003 - "In addition to soluble interleukin 2 receptor (sIL-2R) levels, CRP holds promise as a diagnostic and prognostic index and follow-up monitor in pediatric and adolescent patients with Hodgkin disease, and merits further investigation." 03/01/1998 - "Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications." 01/21/1992 - "We have shown that the major contributory factor to the inhibitory effect of sera from patients with Hodgkin's disease (HD) could be the soluble form of Interleukin-2 receptors (sIL-2R). " 03/01/1990 - "Affinity of IL-2 receptors and proliferation of mitogen activated lymphocytes in Hodgkin's disease."
4.	Hematologic Neoplasms (Hematological Malignancy) 07/15/1995 - "Further, this case illustrates the potential for the use of hematopoietic malignancies in the dog as a suitable animal model for immune targeting of IL-2 receptors as a novel treatment approach for similar malignancies of human beings." 09/01/1993 - "In some conditions, including certain malignant hematologic neoplasms, serum soluble interleukin 2 receptor levels (SIL2R) correlate with disease activity. " 05/15/1989 - "In contrast to these results, most cell lines established from hematopoietic malignancies do not express either chain of the IL-2 receptor. " 05/01/1988 - "The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear." 05/15/1992 - "In the first clinical trial of a genetically engineered ligand fusion-toxin, we have treated 18 patients with chemotherapy-resistant IL-2 receptor expressing hematologic malignancies with escalating doses of DAB486IL-2. "
5.	Neoplasms (Cancer) 12/01/2006 - "In order to reduce normal cell binding, they were modified by preincubation with a recombinant bispecific protein which blocks the viral native cell binding site and introduces a new binding site for a tumor-associated target (in this study, the interleukin-2-receptor, IL-2R). " 12/01/1997 - "However, the yields are still too low to permit the production of material for clinical trials in which the dsFv will be used to image or treat IL2 receptor (CD25)-containing tumors. " 01/01/1994 - "Study of peripheral blood lymphocyte subset distribution and IL-2 receptor (IL-2 R) p55-p75 subunit expression in patients with cancer of different sites." 09/01/1993 - "The correlation of additional variables such as specific activity of DAB486IL-2 and tumor expression of the p75 subunit of the IL-2 receptor and receptor function will also require further study." 06/01/1993 - "The aim of the investigation was to directly study the IL 2 receptor (IL 2 R) and its subunits, p55 and p75 chains, either membrane-bound or soluble, on peripheral blood mononuclear cells (PBMC) of patients with solid malignancies and, indirectly, the same patients' PBMC ability to produce IL 2. Fifty-eight cancer patients, 29 men and 29 women, were studied: their mean age was 57.3 years, range 35-79. "

Related Drugs and Biologics

1.	Interleukin-2 (IL2)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	HLA-DR Antigens (HLA-DR)
4.	Interleukin-6 (Interleukin 6)
5.	Monoclonal Antibodies
6.	Antibodies
7.	daclizumab (dacliximab)
8.	Diphtheria Toxin
9.	Interleukins
10.	Neopterin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Biological Therapy
4.	Renal Dialysis (Hemodialysis)
5.	Homologous Transplantation (Allograft)